- The first patient has been enrolled in a clinical trial, ECLIPSE, assessing Cardiovascular Systems' (NASDAQ:CSII +0.3%) Diamondback 360 Coronary Orbital Atherectomy System in patients with severely calcified coronary arteries.
- The prospective study will enroll ~2,000 subjects with half receiving orbital atherectomy prior to drug-eluting stent (DES) implantation and the other half conventional angioplasty before receiving a DES.
- The FDA approved the Diamondback 360 in October 2013.
Enrollment underway in Cardiovascular Systems' late-stage study of Diamondback atherectomy device compared to angioplasty
Recommended For You
About ABT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ABT | - | - |
Abbott Laboratories |